Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Multiple Myeloma Quizlet
Multiple Myeloma Quizlet
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Multiple Myeloma
What is Multiple Myeloma?
Multiple myeloma, also known as myeloma, hematologic cancer, or cancer of the blood is a plasma cell cancer, a type of white blood cell made in the bone marrow that is responsible for creating antibodies. A Multiple myeloma diagnosis means a group of these plasma cells has become cancerous and is multiplying. This cancerous multiplication of plasma cells raises the the level of abnormal proteins in circulating blood, and reduces the space available in the bone marrow for making healthy plasma cells . Health problems caused by multiple myeloma can affect your bones, immune system, kidneys and red blood cell count. The lifetime risk of getting multiple myeloma is 1 in 149 (0.67%).
What different types of multiple myeloma exist?
IgG is the uncontrolled production of abnormal immunoglobulin (IgG) proteins, which fight bacteria and viruses. This abnormal immunoglobulin has no benefit in the body, and, as it increases in amount, it crowds out normally functioning immunoglobulins. This is the most common types of myeloma, accounting for 60-70% of all cases.
Light chain myeloma is the production of incomplete immunoglobins. Light chain myeloma causes only a portion of the immunoglobin protein (the light chain) to be produced, rendering these immunoglobins incapable of fighting infection. Light chain myeloma accounts for 20 percent of all multiple myeloma diagnosis.
Nonsecretory myeloma forms the level of M protein by producing myeloma cells too low to be detected by standard testing; it accounts for 1-2% of multiple myeloma diagnosis.
What are some symptoms of multiple myeloma?
There are no specific symptoms to detect multiple myeloma early. While symptoms may be present, they are often ve...
... middle of paper ...
...l risk factors that are fully linked developing multiple myeloma. Therefore, preventative measures remain unknown.
Famous people with multiple myeloma:
- Geraldine Ferraro – American attorney (Democratic Party politician)
• http://www.freebase.com/view/en/geraldine_ferraro
- Steve Boros – American Baseball Infielder, Coach, Manager
• http://www.freebase.com/view/en/steve_boros
- Phil Smith – American Professional Basketball player
• http://www.freebase.com/view/en/phil_smith
- Warren William – Broadway & Hollywood actor
• http://www.freebase.com/view/en/warren_william
Created by: Mikayla D. Williams
Peer Reviewed by:
-
Websites:
- http://www.themmrf.org/
- http://www.cancer.org/cancer/multiplemyeloma/index
- http://myeloma.org/Main.action
Since most patients will either have an intact immunoglobulin or a free light chain, quantifying the amount of the M protein will aid in calculating the myeloma tumor burden; staging the myeloma patients; and documenting their response to treatment (Dispenzieri, Lacy, & Greipp, 2004). Moreover, since in 93% of patients a monoclonal protein can be detected in serum and in roughly 70% a monoclonal protein or fragment will be present in urine, according to Nau and Lewis (2008), the diagnosis of an asymptomatic (smoldering) multiple myeloma disease depends on the presence of serum M protein levels of ≥ 3 g/dL; ≥ 10% of bone marrow plasma cells; no related organ or tissue destruction like bone lesions; and no symptoms. On the other hand, the diagnosis of a symptomatic multiple myeloma disease can be accomplished by the presence of M protein in serum and/or urine together with clonal bone marrow plasma cells or plasmacytoma; myeloma-related organ or tissue impairment; and obvious symptoms (Nau, & Lewis,
A 73-year old female presented to St Vincents Emergency Department, with a 3 week history of progressive dyspnoea, cough, and lethargy, on a background of a 6-year history of Multiple Myeloma. Just prior to presentation, she had also developed a fever.
Chronic Myeloid leukemia (CML) is a blood and bone marrow disease that slowly progresses. The disease usually occurs in middle aged or older individuals and rarely occurs in children. In CML, an unusually high number of blood stem cells become granulocytes. These granulocytes, also called leukemia cells are irregular in shape and do not develop into healthy white blood cells. Eventually, they concentrate in the blood leaving no room for healthy cells which may lead to infection, anemia, or bleeding. The typical signs of CML include fatigue, fever, night sweats, and weight loss (6).
Breast cancer has always been a common thread among the women of my family; especially on my mother’s side, including my Grandmother whom passed away due to this disease before I could ever meet her. More so, my mother was gravely affected by this disease early in my life. Thankfully, she was able to stop the cancer from spreading; the doctors were able to find the cancerous cells and remove them. Due to this grave, but powerful impact on my life, I have been determined to becoming a biomedical scientist to assist on the research and treatment of this deadly disease. Although this acts as my principal driver, to study in this field, I have also been intrigued and driven by the idea that I could aid lower setting regions to receive health benefits using studies in translational medicine and
Osteosarcoma, characterized as a neoplasm that produces osteoid, is a highly malignant tumor that develops predominantly in the metaphysis of the long bones, often in the distal femur and proximal tibia. More rare osteosarcomas may develop in the soft tissue. Although the malignancy usually arises in the medullary cavity of the metaphysis of a growing tubular long bone, less frequent growth patterns can develop on the surface on the bone. Surface osteosarcomas, as well as being significantly rarer, are also of a low grade, where else medullary osteosarcomas are of an aggressive nature, making it high grade. Osteosarcomas may also be confined to the cortex, and can even originate in an extraskeletal site.
Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infection, particularly those caused by bacteria or fungi.
With new age purpose and research for the last 60 plus years, LLS has invested over $875 million dollars to advance cancer treatments. LLS invests time in blood cancer research with various programs. Two major programs are Specialized Center of Research (SCOR) and Transitional Acceleration Program (TAP). SCOR's research is surrounded around innovative blood research in the discovery to find the new drugs and treatments. While “through TAP, LLS forges partnerships with universities and biotechnology companies, bringing resources that can more rapidly transform promising research into critically needed therapies, including therapies that might otherwise go undeveloped.”
Sickle-cell anemia is a genetic disorder that makes your body produce red blood cells that are abnormal in shape. This disease is also widely known as hemoglobin SS disease. Unlike normal red blood cells, sickle cells are rigid and tenacious. Due to their shape and rigidness, they can block blood flow. In turn, this could cause organ damage to the body. Sickle cells are also fragile and die very easily due to the fact sickle cells have a lifespan of twenty days instead of the normal one hundred and twenty days for normal red blood cells.This causes the body to have a lower blood cell count, hence the name anemia in sickle cell anemia.
Rodak, B. F., Fritsma, g. A., & Doig, K. (2007). Hematology: Clinical Principles and applications. St. louis: Saunders Elsevier.
This leads to the inflammation and potential damaging of the kidneys and eventual kidney disease unless treated. HSP causes an extreme and severe form of IgAN. There are two forms of IgA, IgA1 and IgA2. IgA1 is the only form involved with HSP. “IgA with diminished hinge-region glycosylation are prone to aggregate into macromolecular complexes. These complexes activate the alternative pathway of complement, and then deposit into the renal mesangium” (Saulsbury). The bodies immune response gets triggered by an upper respiratory illness, and produces IgA antibodies. If these IgA antibodies have hinge regions that are not fully developed correctly then they go haywire; producing more and more and clumping together to form complexes that deposit themselves into the kidneys. These malfunctioning IgA1 antibodies also deposit themselves into blood vessel walls, causing them to rupture and blood to pool at the surface of the skin, the cause of the characteristic purple purpura rash (Saulsbury). Individuals who suffer from HSP do not always produce these malfunctioning IgA antibodies, and many researchers are puzzled by and still researching the “come and go” effect of IgAN affliction in correspondence to
Technical factors should be adjusted accordingly depending on the neoplasm. Positioning should not be altered for this pathology. It is vital that all required radiographs are acquired to aid in the diagnosis of the pathology.
The Phase I trial will be discussed here as it pertains to the topic at hand. The typical treatment for cervical cancer if surgery is not a viable option – like if the cancer has spread, then called locally advanced cervical cancer – is chemotherapy and radiation treatment at the same time. This phase I clinical trial is simply looking to add ipilimumab to this regimen, but once the chemo/radiation has been completed (LACC article). Chemo and radiation destroy tumor cells, which causes tumor-associated antigens to be released. Once released, these antigens are exogenous (outside the cell) and will be presented to helper T cells to initiate an immune response.
For most, the primary fears associated with cancer are connected to the effects of treatments. If the patient is diagnosed when the cancer is still in the early stages, more than likely surgery is the appropriate treatment. However if the cancer has developed into an advanced stage, a more drastic treatment is necessary.
Bone cancer is classified into primary bone cancer & secondary bone cancer. Basically, Primary bone cancer starts in the bone; then the cancer initially forms in the cells of the bone; while the secondary cancer starts elsewhere in the body and gets spread to the bone.
Blood and urine based biomarkers used in molecular pathology are only indicative of the average response of the cell population affected with little or no information of the range of response or variability form areas of tissue (Naddler and Langley 2001)